Vizgen adds Matt Posard to its Board as first Outside Director

– USA, MA –  Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the appointment of Matt Posard to its Board of Directors, guiding to expand market strategies and corporate growth.

“Matt joins our board with an impressive 30 years of commercial and general management expertise in the life sciences industry, combined with a remarkable history of success,” commented CEO, Terry Lo. “His deep knowledge and background of the genomics market will help advance our mission to bring spatial genomics and our MERSCOPE platform to researchers around the world.”

About Matt Posard

A seasoned executive in the genomics and life science space, Matt Posard has an extensive background in launching novel and transformational products, generating high revenue growth, and effectively scaling organizations. Matt held executive positions at Illumina for almost 10 years including global marketing and sales during its first $1B in annual revenue. Matt also served as Senior VP and General Manager of its Translational and Consumer Genomics and New and Emerging Markets business units and was responsible for a notable $100M+ of sales growth in his first year as SVP/GM. Presently, Matt is leading Explore DNA as Founding Principal and serves on many boards for both public and private companies in the life sciences, diagnostics, and therapeutics arena.

“I am deeply honored to be joining Vizgen’s Board of Directors,” said Matt Posard. “The cutting-edge technology offered by Vizgen’s MERSCOPE platform opens an incredible opportunity within the emerging single-cell spatial genomics market, and I look forward to being a part of it. It’s an exciting time for this highly specialized and accomplished team.”

About Vizgen

Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company’s MERSCOPE platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell, and gene therapy, and is an essential tool for accelerating drug discovery and development.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.